Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00082030 · ClinicalTrials.gov registry record

Function of Catecholamines in the Brain During Depression

A clinical trial, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
71
Enrollment target

NCT00082030: Completed study, sponsored by National Institute of Mental Health (NIMH).

NCT00082030 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00082030 has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
71 participants
Enrollment target

Study Summary

This study will explore brain function related to depressive symptoms and will examine DNA for genes that may be involved in depressive disorders, particularly genes that regulate synthesis and metabolism of the brain neurotransmitter catecholamine. It will compare findings in patients with major depressive disorders who are in remission with those in normal, healthy volunteers. Patients with remitted major depressive disorders and healthy normal volunteers between 18 and 60 years of age may be eligible for this study. Candidates are screened with a psychiatric and medical history, physical examination, electrocardiogram, and blood and urine tests. Participants undergo the following tests and procedures in up to eight visits to the NIH Clinical Center: Memory Tasks and Problem Solving and Brain Imaging Subjects are tested with measurements of intelligence or memory ability. They also undergo magnetic resonance imaging (MRI), a test that uses a magnetic field and radio waves to produce images of the brain. For this procedure, the patient lies on a table that is moved into the scanner (a narrow cylinder), and wears earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. The MRI lasts about 60 minutes. Catecholamine Depletion Study For this study, subjects take capsules containing either AMPT (a drug that temporarily reduces brain catecholamine activity) or a placebo (lactose capsules, which do not affect brain catecholamine activity) at 9 a.m., 2 p.m., and 7 p.m. on one visit and return the next day to take additional capsules at 7 a.m. and noon. In addition to the study medication, subjects keep a low-monoamine diet (e.g., no chocolate, cheese, smoked meats, and various other foods that will be enumerated) and do not smoke, drink alcohol, or take in food or drink containing caffeine. After taking all the study capsules, the subjects have positron emission tomography (PET) and functional MRI (fMRI) scans, as follows: * fMRI:

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2004-04-19
Est. Completion 2011-11-18

What the finished NCT00082030 record still lists

NCT00082030 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00082030 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00082030 about?

NCT00082030 is a clinical study titled "Function of Catecholamines in the Brain During Depression". This study will explore brain function related to depressive symptoms and will examine DNA for genes that may be involved in depressive disorders, particularly genes that regulate synthesis and metabolism of the brain neurotransmitter catecholamine. It will compare findings in patients with major de...

What is the current status of trial NCT00082030?

This trial is currently completed. The enrollment target is 71 participants. The study started on 2004-04-19. Estimated completion is 2011-11-18.

Who is sponsoring clinical trial NCT00082030?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00082030, the US trial registry maintained by the National Library of Medicine. NCT00082030 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.